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Objective: Dystrophin is part of a protein complex that connects the cytoskeleton to the
extracellular matrix. In addition to its role in muscle tissue, it functions as an anchoring
protein within the central nervous system such as in hippocampus and cerebellum. Its
presence in the latter regions is illustrated by the cognitive problems seen in Duchenne
Muscular Dystrophy (DMD). Since epilepsy is also supposed to constitute a comorbidity
of DMD, it is hypothesized that dystrophin plays a role in neuronal excitability. Here,
we aimed to study brain dystrophin distribution and expression in both, human and
experimental temporal lobe epilepsy (TLE).
Method: Regional and cellular dystrophin distribution was evaluated in both human
and rat hippocampi and in rat cerebellar tissue by immunofluorescent colocalization
with neuronal (NeuN and calbindin) and glial (GFAP) markers. In addition, hippocampal
dystrophin levels were estimated by Western blot analysis in biopsies from TLE patients,
post-mortem controls, amygdala kindled (AK)-, and control rats.
Results: Dystrophin was expressed in all hippocampal pyramidal subfields and in
the molecular-, Purkinje-, and granular cell layer of the cerebellum. In these regions
it colocalized with GFAP, suggesting expression in astrocytes such as Bergmann glia
(BG) and velate protoplasmic astrocytes. In rat hippocampus and cerebellum there
were neither differences in dystrophin positive cell types, nor in the regional dystrophin
distribution between AK and control animals. Quantitatively, hippocampal full-length
dystrophin (Dp427) levels were about 60% higher in human TLE patients than in post-
mortem controls (p < 0.05), whereas the level of the shorter Dp71 isoform did not differ.
In contrast, AK animals showed similar dystrophin levels as controls.
Conclusion: Dystrophin is ubiquitously expressed by astrocytes in the human and rat
hippocampus and in the rat cerebellum. Hippocampal full-length dystrophin (Dp427)
levels are upregulated in human TLE, but not in AK rats, possibly indicating a
compensatory mechanism in the chronic epileptic human brain.
Keywords: Duchenne muscular dystrophy, dystrophin, epilepsy, seizures, kindling
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INTRODUCTION
Dystrophin is an essential component of a protein complex that
connects the cytoskeleton to the extracellular matrix. Mutations
in the dystrophin gene result in DMD, which is the second most
common genetically inherited disease affecting approximately 1
in 3,500−5,000 life male births (Anderson et al., 2002; Emery,
2002; Emery et al., 2015). The absence of dystrophin leads
to myofiber membrane fragility that results in the progressive
muscular degeneration that characterizes DMD (Sussman, 2002).
Additionally, there is an increasing body of evidence stating
that DMD is associated with non-progressive cognitive and
behavioral deficits (Cotton et al., 2001; Hendriksen and Vles,
2006, 2008; Pane et al., 2012; Snow et al., 2013a) and epilepsy
(Goodwin et al., 1997; Etemadifar and Molaei, 2004; Pane
et al., 2013). This association is thought to result from the
lack of dystrophin within the CNS, where it is normally
located in the hippocampus, prefrontal cortex, and cerebellum
(Chamberlain et al., 1989; Lidov et al., 1993). Different CNS cells
express different Dp isoforms: full-length dystrophin (Dp427)
is localized post-synaptically in neurons, Dp140 is associated
with microvascular glia cells, and Dp71 − the most abundant
dystrophin gene product in the brain – is both expressed in
neurons and glia (Lidov et al., 1995; Blake and Kröger, 2002;
Graciotti et al., 2008).
Functionally, dystrophin expressed in the CNS plays an
important role in the clustering of neurotransmitter receptors
and water- and ion channels to the cellular membrane. The
above mentioned three brain dystrophin isoforms have their
own distinctive functions: neuronal Dp427 is important for the
clustering of GABAA receptors at the post-synaptic membrane
and hence for regulation of inhibitory input (Brünig et al.,
2002). Similarly, Dp71 is mainly involved in the anchoring
and regulation of both the glial water channel AQP-4 and the
glial potassium Kir4.1 channel (Connors et al., 2004; Perronnet
and Vaillend, 2010; Anderson et al., 2012), thereby regulating
water homeostasis and potassium buffering capacity, respectively,
(Hendriksen et al., 2015). As water and ion homeostasis have
powerful effects on neuronal excitability, alterations in the
expression of these dystrophin isoforms may contribute to
hyperexcitability associated with epilepsy by the above mentioned
disturbances (Hendriksen et al., 2015). Finally, the function
of Dp140 is far less well-known: it is expressed in both
brain- and kidney tissue, is particularly expressed during fetal
development (Lidov et al., 1995) and supposed to play some
role in cognitive functioning (Bardoni et al., 2000; Waite
et al., 2012). Consequently, its potential theoretical relation with
epileptogenesis is hard to speculate upon and hence this isoform
will not be further discussed in this paper.
Abbreviations: AK, amygdala-kindling; AQP-4, aquaporin 4; BG, Bergmann
glia; CA, cornu ammonis; CNS, central nervous system; DG, dentate
gyrus; DMD, Duchenne muscular dystrophy; Dp, dystrophin protein; EEG,
electroencephalography; FDG-PET, fluorodeoxyglucose positron emission
tomography; GABAA, gamma-aminobutyric acid type A; GCL, granular cell layer;
GFAP, glial fibrillary acidic protein; HS, hippocampal sclerosis; KA, kainic Acid;
Kir4.1, inwardly rectifying potassium; MCL, molecular cell layer; MR, magnetic
resonance; NeuN, neuronal nuclei; PC, Purkinje cell; PCL, Purkinje cell layer;
TLE, temporal lobe epilepsy.
In this study, we evaluated dystrophin expression in human
and experimental TLE. Analogous to the preferred method of
detection for muscular dystrophin, we used a combination of
descriptive immunofluorescence and Western blot (Anthony
et al., 2014) to assess dystrophin expression in the hippocampus
and cerebellum – two of the major brain structures containing
dystrophin -, as the hippocampus plays a major role in the
pathogenesis of TLE (Racine et al., 1972; Sloviter, 1994), whereas
the cerebellum is supposed to play a potential role in effective
anti-epileptic neuromodulation (Velasco et al., 2008; Al-Otaibi
et al., 2011). Consequently, the aim of this study was, first,
to evaluate regional and cellular dystrophin distribution in
the aforementioned two anatomical brain regions by means
of immunofluorescence and, second, to assess whether there
were quantitative differences in dystrophin expression between
epileptic and control individuals by means of Western blot
analysis.
MATERIALS AND METHODS
Ethical Statement
All procedures performed in studies involving human
participants were in accordance with the ethical standards
of the institutional and/or national research committee and
with the 1964 Helsinki declaration and its later amendments
or comparable ethical standards. Written informed consent
was obtained from all individual participants included
in the study. All applicable international, national, and/or
institutional guidelines for the care and use of animals were
followed. All procedures performed in studies involving
animals were in accordance with the ethical standards
of the institution or practice at which the studies were
conducted.
Amygdala Kindling Model
Animals
Male 10-week-old Sprague−Dawley rats, purchased from Harlan
(Horst, Netherlands) were kept under controlled conditions
(21 ± 2◦C ambient temperature, a 12 h light/dark schedule,
background noise provided by radio and food and water
available ad libitum). The animals were habituated 1 week
to the experimenter and the housing before the start of the
experiment. All experimental procedures were approved by
the local animal ethics committee of Maastricht University
and complied with national and international governmental
legislation.
Surgery
Twenty-four rats were implanted with an electrode for AK. Thirty
minutes before surgery, the rats received 0.1 ml buprenorphine
(Temgesic) subcutaneously for perioperative pain relief.
The surgical procedures took place under general isoflurane
anesthesia (5% for induction and 2,5% for maintenance).
A standard rat stereotact (Stoelting Europe, Dublin, Ireland)
was used for implanting the electrode in the rats. The bipolar
platinum/iridium needle of the electrode, with a tip diameter
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of 200µm, was implanted in the left basolateral amygdala
(coordinates relative to bregma: 2,5 mm posteriorly, 4,8 mm
laterally, and 9,6 mm ventrally) (Paxinos and Watson, 1986).
Also one stainless screw was implanted over the nasal sinus,
which served as reference. The connector was fixed on the skull
using dental acrylic cement.
Amygdala Kindling Procedure
Amygdala kindling started 10 days after the electrode
implantation and was performed as described previously
(Aalbers et al., 2009, 2014; Rijkers et al., 2010). Initially,
stimulation was performed twice daily (first stimulus between
8 and 10 AM, second stimulus between 2 and 4 PM; an
interstimulus-interval > 6 h) with the following parameters:
2 s, 400 µA, 50 Hz, 0.2 ms block pulses. A stimulus intensity
of 400 µA was chosen to assure that the intensity was above
the after discharge threshold for all rats. Stimuli were delivered
through a WPI Accupulser A310 connected to a WPI Stimulus
Isolation Unit A360 (World Precision Instruments, Sarasota, FL,
USA).
All rats were videotaped (Olympus FE-330) during
delivery of the kindling stimulus and for as long as the
behavioral seizure lasted. Seizure severity was evaluated
oﬄine from video-recordings by two blinded observers
and classified according to the Racine scale (Racine et al.,
1972). After reaching the fully kindled state, defined as
five consecutive stage five seizures, rats received one AK-
stimulation per day for two more weeks. Sham rats (N = 8)
received an amygdala electrode that was not stimulated. Rat
tissue processing protocols, i.e., for immunofluorescence
and Western blot, are further described in the respective
sections.
Human Tissue
Surgery
Human hippocampi were intra-operatively obtained between
2010 and 2015 at Maastricht University Medical Centre
(MUMC+). All patients suffered from medically refractory
TLE (Kwan et al., 2010). Prior to the study, written informed
consent was obtained from each patient. Extensive pre-surgical
evaluation included video-EEG monitoring, neuropsychological
testing and MR-imaging in all patients and occasionally FDG-
PET. Surgical hippocampal specimens were evaluated and
sclerosis was graded by a trained observer of the pathology
department of MUMC+, after which the samples were encoded.
In total, 15 TLE patients (mean age ± SEM = 39.7 ± 4.1 years;
8 males) were included, of which nine patients suffered
from severe HS, whereas 6 did not show any signs of
HS. Hippocampal tissue obtained at autopsy (N = 9; mean
age ± SEM = 67.3 ± 3.4 years; all male) served as non-epileptic
control tissue. Patient characteristics for all included patients are
provided in Table 1.
Tissue Preparation
Immediately after surgical resection, the hippocampi were cooled
for 1 min at 4◦C 0.9% saline and then dissected into two parts
perpendicular to the longitudinal axis. One part was fixed in 4%
paraformaldehyde overnight at 4◦C, embedded in paraffin, and
used for routine histopathological evaluation. The other part was
immediately frozen on dry ice and stored at −80◦C until further
analysis (Aalbers et al., 2014).
Immunofluorescence
Rat Tissue
Two or 24 h after the last seizure, rats were sacrificed and
processed for immunofluorescence as described previously. Rats
received an overdose of pentobarbital (Nembutal, 0.1 mg/kg
body weight) and were then trans-cardially perfused with
0.5 M ice cold phosphate buffered saline (PBS) followed by 4%
paraformaldehyde in 0.5 M PBS. Brains were dissected and post-
fixed in 4% paraformaldehyde/0.5 M PBS for 90 min. Next, brains
were cryoprotected by immersion in 20% sucrose/0.5 M PBS
for 24 h. Subsequently, the brains were frozen by immersion in
−40◦C isopentane for 3 min and stored at −80◦C until further
analysis by immunofluorescence.
For immunofluorescence, 50µm sagital sections of the
right cerebellum (50µm, free floating) and coronal sections
of the left hippocampus (30µm, free floating) were serially
cut using a cryostat. Free-floating sections were successively
incubated at room temperature for 30 min in 1 M tris-
buffered saline (TBS), and subsequently with 0.5% Triton
X-100, and 10% normal donkey serum (NDS) for 60 min.
Then, sections were incubated overnight at 4◦C in TBS
containing 0.5% Triton X-100 and 10% NDS − for NeuN
(neuronal nuclei) in hippocampus − or PBS − for GFAP
(glial fibrillary acidic protein) and calbindin in cerebellum
and GFAP in hippocampus -, and rabbit polyclonal anti-
dystrophin (Abcam, Ab15277, Cambridge, UK, diluted 1:500),
followed by donkey anti-rabbit secondary antibody conjugated
to Alexa 488 (Invitrogen, Carlsbad, CA, USA, diluted 1:200).
For the cerebellum, sections were incubated overnight with
monoclonal mouse anti-calbindin D-28k (SWANT, McAB 300,
Marly, Switzerland, diluted 1:25,000) as a marker for PC or with
monoclonal mouse anti-GFAP (Sigma−Aldrich, G3893, Saint-
Louis, MO, USA, diluted 1:500) as a marker for astrocytes.
Hippocampal tissue was also stained with monoclonal mouse
anti-GFAP (Sigma−Aldrich, G3893, Saint-Louis, MO, USA,
diluted 1:500) and additionally with monoclonal mouse NeuN
(Millipore, mab377, Darmstadt, Germany, diluted 1:50) as a
marker for neuronal nuclei. Primary antibodies were detected by
donkey anti-mouse secondary antibody conjugated with Alexa
594 (Invitrogen, Carlsbad, CA, USA, diluted 1:200). Finally,
a Hoechst (Sigma−Aldrich, Saint-Louis, MO, USA) staining
(1:500) was performed at room temperature and after washing,
the sections were coverslipped with 80% glycerol. Negative
controls were incubated with non-immune serum. Rat biceps
femoris muscle sections were used as a positive control for
dystrophin immunofluorescence.
Additionally we performed triple staining− due to the unclear
subcellular localisation of the dystrophin protein in the cerebellar
sections − with the following primary anti-bodies: rabbit anti-
dystrophin (Abcam, Ab15277, Cambridge, UK, diluted 1:500),
monoclonal mouse anti-calbindin D-28k (SWANT, McAB 300,
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TABLE 1 | Clinical characteristics of subjects used for Western blotting analysis.
Control Gender Age (years) Cause of death Pathology Hippocampus Side Classification
1 Male 64 Natural Unremarkable Right Non-epileptic
2 Male 66 Natural Unremarkable Right Non-epileptic
3 Male 76 Sepsis, POB Unremarkable Left Non-epileptic
4 Male 80 Heart Failure Unremarkable Right Non-epileptic
5 Male 66 Unknown Unremarkable Right Non-epileptic
6 Male 61 MI-resuscitation Unremarkable Right Non-epileptic
7 Male 83 MI-resuscitation Unremarkable Right Non-epileptic
8 Male 55 Sepsis, MOF Unremarkable Unknown Non-epileptic
9 Male 55 Cardiac after PE Unremarkable Right Non-epileptic
Case Gender Age (years) Pathology Hippocampus side Classification
1 Male 35 − Mesial temporal sclerosis Right Epileptic: severely sclerotic
2 Female 50 − mesial temporal sclerosis Right Epileptic: severely sclerotic
3 Male 63 − Mesial temporal sclerosis Right Epileptic: severely sclerotic
4 Female 43 − Mesial temporal sclerosis and
microdysgenesis (possibly in relation to
cortical dysplasia)
Right Epileptic: severely sclerotic
5 Male 19 − Mesial temporal sclerosis & FCD 2A Right Epileptic: severely sclerotic
6 Female 58 − Mesial temporal sclerosis Right Epileptic: severely sclerotic
7 Male 33 − Mesial temporal sclerosis Left Epileptic: severely sclerotic
8 Female 20 − Mesial temporal sclerosis Left Epileptic: severely sclerotic
9 Female 37 − Mesial temporal sclerosis Left Epileptic: severely sclerotic
10 Male 55 − DNET, right temporal side (WHO dgr. 1) Right Epileptic: non-sclerotic
11 Male 16 − Venous malformations in amygdala Right Epileptic: non-sclerotic
12 Female 64 − Brain aneurysms (communicans
posterior and cerebri media)
Right Epileptic: non-sclerotic
13 Male 41 − Reactive cortical gliosis Right Epileptic: non-sclerotic
14 Male 24 − History of right-sided skull-base
meningeoma
Right Epileptic: non-sclerotic
15 Female 38 − Unremarkable Right Epileptic: non-sclerotic
M, Male; F, Female; POB, Post-operative bleeding; MI, Myocardial Infarction; MOF, Multi- Organ Failure; PE, pulmonary embolism; FCD, Focal Cortical Dysplasia; DNET,
Dysembryoplastic Neuroepithelial Tumors.
Marly, Switzerland, diluted 1:2,500) and polyclonal goat anti-
GFAP (Santa Cruz Biotechnology, C-19, Heidelberg, Germany,
diluted 1:200). All primary antibodies were diluted in 1% NDS
in 0.5% PBS-T and simultaneously incubated at 4◦C for 16 h
after blocking for 1 h with 10% NDS. Secondary antibodies
used were: Donkey anti-mouse secondary antibody conjugated
to Alexa 647 (Abcam, Cambridge, UK, diluted 1:200), donkey
anti-rabbit secondary antibody conjugated to Alexa 488 (Abcam,
Cambridge, UK, diluted 1:200), donkey anti-goat secondary
antibody conjugated to Alexa 594 (Invitrogen, Carlsbad, CA,
USA, diluted 1:100). All secondary antibodies were diluted
in 1% NDS in 0.5% PBS-T and simultaneously incubated at
room temperature for 2 h. After washing, the sections were
coverslipped with 80% glycerol.
Human Hippocampus Tissue
Paraffin-embedded human hippocampal sections of 4µm were
cut in a coronal plane and directly mounted on glass. Sections
were deparaffinized, followed by antigen-retrieval (0.01 M
citric acid in a water bath of 95◦C for 20 min, followed
by 20 min of cooling). Sections were immunohistochemically
stained as described above using the following antibody
concentrations: rabbit anti-dystrophin (1:100), mouse anti-
GFAP (1:500), NeuN (1:50), Alexa 488 (1:100), and Alexa 594
(1:100).
Image Acquisition
Photomicrographic images were made using a BX51-microscope
(Olympus, Tokyo, Japan) connected to an Olympus XC10 camera
(Olympus, Tokyo, Japan), which generated 16-bits TIFF files.
Images were taken with different exposure times for the different
fluorophores. Exposure times were kept constant among all
sections, thereby only being filter-specific (DAPI/Hoechst 1 ms,
TXRED 1000 ms, and FICT 1000 ms). Additionally, confocal
1µm space stacks were made of neuronal and glial cells in
hippocampal sections (600 times magnification), PC in cerebellar
sections (1000 times magnification, not shown) and the cerebellar
triple staining (400 times magnification) by means of a confocal
disk spinning unit microscope (Olympus, Tokyo, Japan) financed
by The Netherlands Organisation for Scientific Research (grant
number 911-06-003). In the immunostainings of human tissue,
all pictures were taken from the GCL of the DG.
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Western Blot
Tissue Preparation
Rats were sacrificed 2 (i.e., acute group, N = 8) or 24 h
(i.e., chronic group, N = 8) after their last seizure. For the
collection of hippocampal samples, rats were decapitated, brains
were removed, right-side hippocampi were isolated by dissection
and frozen at −80◦C until further analysis. The right side was
chosen since this is contralateral to the stimulation site, hence
preventing potential confounding by the effects of direct electrical
stimulation.
Each hippocampus (i.e., rat and human) was separately
homogenized in lysis buffer (1 g tissue per 9 ml lysis
buffer) containing 0.01 M PBS, 1% Igepal, 0.1% Triton X-100,
1 mM EGTA (ethylene glycol tetraacetic acid), 1 mM EDTA
(ethylenediaminetetraacetic acid), and protease inhibitor (Roche
Custom Biotech, ML758, Penzberg, Germany).
For the limited amount of rat cerebellar tissue available (sham
control and AK acute group; both N = 4), proteins were extracted
from paraformaldehyde fixed sections using an extraction buffer
kit according to the manufacturer’s instructions (Qiagen, Venlo,
the Netherlands).
Western Blot Protocol and Quantification
After estimating the total protein concentration per sample using
a bovine serum albumine standard curve (BioRad, Hercules, CA,
USA), proteins (40 µg per lane for homogenate) were separated
by gel electrophoresis using a 7.5% polyacrylamide gel containing
20% SDS. Each sample was run in duplicate. Proteins were
subsequently transferred to a PVDF membrane (Merck Millipore,
Billerica, MA, USA) for 16 h at 35V. After a 2 h blocking
step in commercial Odyssey blocking buffer (diluted 1:2 with
PBS and 5% NDS), the membrane was incubated overnight at
4◦C with polyclonal rabbit anti- dystrophin (Abcam, Ab15277,
Cambridge, UK, diluted 1:100) and subsequently for 1 h with goat
anti-rabbit IRDye 800CW (LI-COR, Homburg, Germany, diluted
1:10,000) in blocking buffer. Rat muscle (m. biceps femoris) was
used as a positive control and only showed the Dp427 isoform
(not shown). Immunoreactive protein bands were visualized
by an Odyssey infrared imaging system (Li-COR Biosciences,
Lincoln, NE, USA) (Cooper et al., 2003). Optical density values
were normalized to glyceraldehyde-3-phosphate dehydrogenase
(GAPDH), detected by mouse monoclonal anti-GAPDH primary
(Fitzgerald Industries International, Acton, MA, USA, diluted
1:2,000,000) and donkey anti-mouse IRDye 680RD (LI-COR,
Homburg, Germany, diluted 1:10,000) secondary antibody.
Immunoblots were analyzed with ImageJ software (Anthony
et al., 2014). Relative pixel intensities were measured and the
background signal was subtracted (Taylor et al., 2013). Every
dystrophin isoform was corrected for by its respective GAPDH
expression and subsequently expressed as a percentage of the
average of the sham’s rats or post-mortem control patients’
expression on the respective gel (Anthony et al., 2014). During
quantification, the observer was blinded to the experimental
condition to prevent biased assessment. Typical examples of
western blots are depicted in Figures 6C,F, and 7C.
Data Analysis
Quantified blot intensities were averaged of at least two
independent experiments (and thus two or more samples per
animal) within groups and were expressed as the mean + SEM.
These values were then used to calculate group averages.
In order to evaluate the effect of kindling on dystrophin
expression, we compared levels of sham and kindled animals
by a Mann−Whitney U test. To compare the acute effect with
the long-lasting effect of a seizure on dystrophin expression in
the hippocampus, we compared rats that were sacrificed 2 and
24 h after a seizure by, again, a Mann−Whitney U test. Because
two tests were performed, we corrected the alpha of 0.05 by
Bonferroni to 0.025.
FIGURE 1 | Immunofluorescent overview staining of rat hippocampus (A) and rat cerebellum (B) in order to evaluate dystrophin expression in an
animal model for TLE, 100 times magnification. (A) Hippocampal DG, consisting of the GCL is stained purple due to colocalization between NeuN (red) and
Hoechst (blue) and is surrounded by dystrophin (green) positive astrocytes and blood vessels through all different hippocampal layers. (B) The three cerebellar layers
can be clearly distinguished: from right to left note the completely red MCL as a consequence of densely packed PC processes, the PCL as visualized by the
calbindin (red) antibody, and finally the GCL which mainly consists of dystrophin (green) positive cells and blood vessels. GCL, granular cell layer, MCL, molecular cell
layer, PCL, Purkinje cell layer.
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Similarly, for human hippocampi, we compared dystrophin
levels in epileptic and non-epileptic tissue, using a
Mann−Whitney U test. In order to assess the influence of
neuronal cell loss and gliosis, we also evaluated the difference
in dystrophin expression between epileptic patients with and
without HS, according to an alpha level of 0.025.
RESULTS
Regional and Cellular Brain Dystrophin
Distribution
Rat Brain Dystrophin Distribution
Dystrophin distribution was studied in rat hippocampus and rat
cerebellum. A general overview of these examined anatomical
regions is depicted in Figure 1 by means of low-power images.
Hippocampus
Morphologically, no global changes (e.g., granular cell
dispersion) or differences were detected when comparing
sham rat hippocampus with AK rat hippocampus as proven by
H&E staining (Figure 2). Dystrophin is present in multiple layers
of the hippocampus. In the rat hippocampus it is ubiquitously
expressed around the pyramidal cell layer of CA1 through CA4
as well as in the hilus and around the GCL of the DG. The
morphological appearance of dystrophin suggests expression
of dystrophin in blood vessels and astrocytes (Figures 3A−H).
Indeed there is a strong colocalization between dystrophin
and GFAP positive astroglia (Figures 3A,B,G). Both in the
pyramidal cell layer and in the GCL, there was no colocalization
present between dystrophin and the neuronal marker NeuN
(Figures 3C−F,H). The regional and cellular distribution of
dystrophin did not differ between sham control and AK rats.
Cerebellum
Dystrophin is present in the MCL, the PCL, and GCL of
the cerebellum (Figure 4). Morphologically, it appears to be
present around PC, in astrocytes of both the MCL and GCL,
and in blood vessels across all three cerebellar layers. The
somata of PC located within the PCL are surrounded by
dystrophin immunoreactivity, hence either reflecting PCs or BG.
Triple-immunostaining (Figure 4E) shows clear colocalization
with GFAP but not with the neuronal calbindin protein, thus
confirming the dystrophin positive BG surrounding individual
PC. The diffuse dystrophin immunoreactivity in the GCL and
the colocalization with GFAP reflects dystrophin positive velate
protoplasmic astrocytes in this layer (Figures 4A,B). The regional
and cellular distribution of dystrophin did not differ between
sham control and AK rats.
Human Brain Dystrophin Distribution
Analogous to the rat hippocampal tissue, the morphological
appearance of dystrophin in human hippocampal tissue suggests
expression of dystrophin in blood vessels and astrocytes
(Figure 5B). Indeed strong colocalization between dystrophin
and GFAP positive astroglia appears again (Figures 5D,F). Based
on a general visual examination in all performed stainings,
FIGURE 2 | H&E-staining of (dorsal) hippocampus of a sham rat (A)
and AK rat (B), coronal section, 20 times magnification. No global
differences in morphology (e.g., granular cell dispersion or pyramidal cell loss)
could be noted. CA = cornu ammonis; DG = dentate gyrus.
the amount of dystrophin positive astrocytes seems to be
higher in the epilepsy patient (Figure 5D) (here: non-sclerotic)
compared to the post-mortem control (Figure 5C). That is,
here, only one astrocyte is stained yellow in this post-mortem
control tissue, whereas three others (black arrowheads) are red
(Figure 5E), compared to at least six yellow astrocytes and zero
red, none-colocalizing astrocytes, in the non-sclerotic epileptic
tissue of Figure 5F. In the NeuN/dystrophin double-staining
no colocalization pattern was found in post-mortem control
tissue (Figure 5A), nor in TLE patients within the epileptic
conditions (Figure 5B). It should be noted that the dystrophin
distribution pattern was similar for sclerotic and non-sclerotic
patients, therefore no visual distinction could be made and hence
only the images of an epileptic, non-sclerotic patient are shown
here.
Quantitative Brain Dystrophin levels in
Epilepsy
Amygdala Kindled Rats
Western blotting demonstrated that the full-length isoform
(Dp427), Dp140, and Dp71 are expressed in the hippocampus
and cerebellum of AK rats (see Figures 6C,F and 7C for a typical
example).
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FIGURE 3 | Immunofluorescent staining of dystrophin distribution in rat hippocampus. Double staining for dystrophin (green) and GFAP (red) (magnification
400 times) reveals colocalization (yellow signal) of GFAP and dystrophin in rat hippocampal sections of a control rat (A) and a similar colocalization pattern of GFAP
and dystrophin is present in the hippocampus of AK rats (acute condition) (B). No colocalization is present in the double-labeled immunofluorescent staining for
dystrophin (green) and NeuN (red) (magnification 200 times) in and around the pyramidal cell layer of the CA3 region in sham rat tissue (C) nor in AK (acute) rat
(D). There is also no colocalization between dystrophin (green) and NeuN (red) (magnification 400 times) in the hilus between the DG and CA3 in control rat
hippocampus (E) or AK (acute) rat hippocampus (F). (G,H) (sub)cellular distribution of dystrophin in rat hippocampus (DG) as visualized by confocal microscopy
(magnification 600 times). (G) One micrometer spacing stack through the hippocampus of a sham rat stained for dystrophin (green) and GFAP (red), white
arrowheads indicate dystrophin positive, colocalizing astrocytes. (H) One micrometer spacing stack through the hippocampus of a sham rat stained for dystrophin
(green) and NeuN (red), black arrowheads indicate dystrophin positive (perivascular) astrocyte-like cells. Asterisks indicate dystrophin positive blood vessels.
Sham = control rat, AK = Amygdala Kindled rat (here: acute AK rat; i.e., sacrificed 2 h after the last seizure).
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FIGURE 4 | Dystrophin distribution in rat cerebellum (sagital sections), 400 times magnified. (A) Sham rat section stained for dystrophin (green) and GFAP
(red). (B) AK (acute) rat section stained for dystrophin and GFAP. Note the colocalization between GFAP and dystrophin (in both A,B), hence revealing BG in yellow,
which are extending from the molecular layer and surround the PC. There is also co-expression in the GCL between GFAP and dystrophin, thereby possibly
reflecting dystrophin positive velate protoplasmic astrocytes (white arrowheads). (C) Dystrophin (green) and calbindin (red) expression in sham rat cerebellum.
(D) Dystrophin and calbindin expression in the cerebellum of an (acute) AK rat. There is no clear co-expression of dystrophin with calbindin positive PC in (C,D).
(E) Triple staining in sham/control rat tissue with dystrophin (red), GFAP (green), and calbindin (gray) visualized by means of confocal microscopy, solely performed in
order to assess which cell types here express dystrophin. Dystrophin is visible in blood vessels and in BG (indicated by white arrowheads), both around the PC −
where the soma of the BG is located − but also in the processes within the MCL. Calbindin is depicted in gray and stains the PC as such, yet does not colocalize
with dystrophin. Note the presence of multiple blood vessels in all three layers of all images. Sham = control animal, AK = Amygdala Kindled animal (here: acute AK
rat; i.e., sacrificed 2 h after the last seizure).
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FIGURE 5 | Immunofluorescence of dystrophin distribution in human hippocampus of a post-mortem control patient (A,C,E) and a TLE patient
without sclerosis (B,D,F). (A) NeuN (red) in the GCL of the DG without dystrophin (green) positive astroglial-like cells in post mortem control tissue. Next, none of
these NeuN positive cells are stained yellow and are therefore dystrophin negative, 100 times magnification. (B) NeuN staining revealing NeuN (red) in the GCL of the
DG and many dystrophin (green) positive astroglial-like cells in the hippocampus (DG) of a TLE patient, 100 times magnification. Again, no colocalization is observed.
(C) GFAP (red) but not dystrophin (green) positive astrocytes (indicated by means of black arrowheads) around the DG in the hippocampus of a post-mortem control
patient, 200 times magnification. (D) Dystrophin positive astrocytes around the DG of an epileptic hippocampus, revealing clear (yellow) colocalization, double
stained for dystrophin (green) and GFAP (red), 200 times magnification. (E) 400 times magnified close-up of the DG of a post-mortem control patient. The white
arrowhead indicates a glial cell that reveals some colocalization between GFAP (red) and dystrophin (green), whilst the black arrowheads indicate none colocalizing
astrocytes. (F) 400 times magnified close-up of an area within the DG of a TLE patient. The white arrowheads depicted indicate, again, glial cells that show (yellow)
colocalization between GFAP (red) and dystrophin (green). Asterisks indicate dystrophin positive blood vessels.
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FIGURE 6 | Mean values of relative dystrophin expression in hippocampus and cerebellum of sham and AK rats (SEM’s are indicated with whiskers).
(A) Dp427 expression in sham rats (N = 8) versus acute AK (N = 7) and chronic AK rats (N = 8). (B) Dp71 expression in again sham rats (N = 8) versus acute AK
(N = 8) and chronic AK (N = 8) rats. (C) An example of the performed Western blot technique for dystrophin (in green) in rat hippocampus. The different isoform
bands as well as the GAPDH bands (red) are indicated. (D) Dp427 expression in the cerebellum of sham rats (N = 4) versus (acute) AK rats (N = 4). (E) Dp71
expression in again sham rats (N = 4) and (acute) AK rats (N = 4). (F) Typical example of Western blot performed in cerebellum. S = sham/control rat, A = acute AK
rat (sacrificed 2 h after last seizure), C = chronic AK rat (sacrificed 24 h after last seizure).
The relative dystrophin expression for both isoforms (i.e.,
Dp427 and Dp71) in rat hippocampus was on average neither
statistically significantly different between sham and AK rats
(Figures 6A,B, sham vs. all AK rats pooled p = 0.506 for Dp427
and p = 0.081 for Dp71), nor between acute AK and chronic
AK rats (Figures 6A,B, acute AK vs. chronic AK p = 0.694 for
Dp427 and p = 0.88 for Dp71). In the cerebellum no statistical
differences could be detected either (Figures 6D,E, p = 0.343 for
Dp427 and p= 0.686 for Dp71).
Human TLE
For the control tissue, the post-mortem delay time was
minimized (average time ± SEM = 1112 ± 175 min). In
addition, dystrophin expression intensity did not correlate with
post-mortem delay (Pearson’s R = 0.28, p = 0.47); hence the
post-mortem delay did not influence the analysis.
Dp427 expression was on average 59.8% higher (SEM post-
mortem control group: 10.7%; SEM pooled epilepsy group:
26.9%) in TLE patients (N = 15; p = 0.023), whereas
Dp71 expression was not significantly increased in epileptic
patients (+8.4%; p = 0.682; Figure 7). Furthermore, there was
no statistically significant difference in dystrophin expression
between severely sclerotic and non-sclerotic hippocampi from
TLE patients (data not shown, p-values of 0.689 and 0.955 for
Dp427 and Dp71, respectively).
DISCUSSION
Here, we evaluated the hippocampal and cerebellar distribution
of dystrophin in TLE patients and in an animal model of TLE
(I) qualitatively by means of immunofluorescence in order to
assess both the regional and cellular distribution pattern, and
(II) quantitatively by means of Western blot analysis. We have
shown that dystrophin is expressed in different types of glial cells
in multiple layers of both the hippocampus and the cerebellum.
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FIGURE 7 | Mean values of relative dystrophin expression in the hippocampus of patients operated for therapy-resistant TLE by means of
neurosurgical removal of the hippocampus, compared to post-mortem controls (SEM’s are indicated with whiskers). (A) Dp427 expression in
post-mortem controls (N = 8) versus epilepsy patients, both with severe sclerosis and without sclerosis (total N = 15). ∗Significant at alpha < 0.025. (B) Dp71
expression in again hippocampus from post-mortem control patients (N = 9) and in hippocampus from all patients included with TLE (i.e., with and without severe
sclerosis; N = 15). (C) Example of Western blot performed in human hippocampus tissue; it is interesting to note the aspecific dystrophin (green) bands, especially
below Dp71. Abbreviations in panel C: W = without/no sclerosis, S = severe sclerosis, C = post-mortem control.
Surprisingly, no expression of dystrophin in neuronal cells – like
granular cells in the hippocampus or PC in the cerebellum – was
found. In rats, the dystrophin distribution pattern did not seem
to differ between sham control and AK conditions. Furthermore,
the amount of dystrophin expression was not different between
control and kindled animals. In human hippocampi from TLE
patients there was, however, a significant increase in the amount
of Dp427 when pooling all TLE samples.
Regional and (Sub) Cellular Brain
Dystrophin Distribution
It is unclear why we did not detect neuronal dystrophin
expression in rat tissue, as the used dystrophin antibody is
directed against the carboxy-terminal of the protein and hence
supposed to detect all isoforms as also demonstrated by Western
Blot. Possibly, the abundantly present Dp71, which is the most
numerous dystrophin isoform in the brain (Lederfein et al., 1992;
Aleman et al., 2001), may have overshadowed the expression
of Dp427 as it may have led to saturation of the antibody.
Yet increasing antibody concentrations as well as augmented
incubation times did not alter the expression pattern. Moreover,
Dp71 is also present in neurons (Austin et al., 2000; Aleman et al.,
2001) and nonetheless no colocalization was observed.
The presence of dystrophin in cerebellar PC has been
previously debated, i.e., whereas some studies report on
expression in the soma (including cytoplasm and plasma
membrane) and the dendritic tree (Huard and Tremblay, 1992),
others show that dystrophin is confined to the somatic membrane
(Snow et al., 2013b). The diffuse cytoplasmic labeling might be
explained by the use of biotinylated antibodies in some studies
(Huard and Tremblay, 1992), which may bind to endogenous
biotin in PC (Snow et al., 2013b) or by the presence of auto-
fluorescence, which is known to occur in the center of PC somata
through the accumulation of lipofuscin (Barden, 1980; Schnell
et al., 1999). In this study, we checked for auto-fluorescence by
microscopic evaluation of unstained sections, which confirmed
its absence.
The immunoreactivity surrounding the soma of the PC here
might be attributable to Dp71 (Moukhles and Carbonetto, 2001;
Figure 4) and thus might reflect BG as their cell bodies are
located in the PCL. Besides, these specific glial cells are known
to intimately embrace PC (Tanaka et al., 2008). Indeed, a
triple staining performed in this study showed colocalization of
dystrophin with GFAP but not calbindin (Figure 4E). In the rat
cerebellum dystrophin was immunohistochemically also present
in astrocytes within the GCL, thereby possibly representing velate
protoplasmic astrocytes (Hoogland and Kuhn, 2010), which is
in contrast to the finding that dystrophin immunoreactivity
in the GCL is limited to blood vessels (Blake et al., 1999).
Additionally, dystrophin was present in astrocytes in the MCL
(Figure 4), thereby reflecting Dp71 positive BG as proposed
earlier (Moukhles and Carbonetto, 2001).
Quantitative Dystrophin Levels in
Epileptic Brain Tissue
Based on quantitative Western blot analysis, there were
no significant differences in dystrophin expression between
kindled and sham control animals. In line with our results,
hippocampal dystrophin levels were not altered in other pre-
clinical epilepsy models such as the pentylenetetrazole and
status epilepticus model (Gorecki et al., 1998; Kim et al.,
2010). Knuesel et al. (2001), on the other hand reported
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regional specific alterations by making use of the KA model
for TLE, a model that is followed by progressive morphological
alterations (Bouilleret et al., 1999). This model demonstrated
a Dp71 upregulation in the hippocampal molecular layer, yet
a downregulation in the GCL (Knuesel et al., 2001). The
contradicting effect of up- and downregulation within the same
structure might have led to a net difference of approximately zero,
which may explain the results in our study in which a homogenate
of the full hippocampus was evaluated. However, we could not
detect any major regional differences by visual inspection of the
immunofluorescent stained rat hippocampus sections.
In contrast, the human Western blot results demonstrated
increased Dp427 levels in hippocampi from drug-resistant TLE
patients compared to post-mortem controls. This finding is
in contrast to the studies hitherto performed that revealed a
reduction of hippocampal dystrophin (Lee et al., 2004; Das et al.,
2012) or even an absence of perivascular Dp71 from sclerotic
hippocampus, specifically in the CA1 region (Eid et al., 2005).
However, such Dp71 alterations might be region specific since
in the subiculum of the same HS patient a strong dystrophin
signal could be observed in and around the capillaries, which
was furthermore comparable to the signal observed in the non-
HS subiculum (Eid et al., 2005). In contrast, here we did not
observe such substantial differences in any sclerotic hippocampal
region (images not shown). Yet, as can be deduced from these
recordings, dystrophin is visible in and around the GCL and
MCL of the DG in severely sclerotic hippocampus. Furthermore,
the Western blots (Figure 7C) in this study instantly reveal
expression of Dp71 in the hippocampus of epilepsy patients with
severe sclerosis, which may thereby further support the notion of
region specific alterations in hippocampal dystrophin, as earlier
described by Knuesel et al. (2001) in rat tissue.
The dystrophin increase (here: only Dp427) in epileptic
hippocampi could theoretically be explained as a compensatory
upregulatory mechanism. Dp427 and Dp71 have powerful effects
on excitation by clustering of postsynaptic GABAA-receptors
(Brünig et al., 2002) and astrocytic AQP-4 and Kir4.1 channels
(Connors et al., 2004; Perronnet and Vaillend, 2010), respectively,
(Hendriksen et al., 2015).
However, non-neuronal dystrophin, as shown in this study
by means of immunohistochemical stainings, does not only
cluster the aforementioned two channels but also plays a role
in blood-brain barrier functioning. That is, Dp71 binds actin
filaments between endothelial cells and is consequently able to
influence vascular permeability (Tinsley et al., 1994). This way,
Dp71 may, again, be related to hyperexcitation (Hendriksen
et al., 2015). Additionally, evidence suggests that Dp71 clusters
post-synaptic proteins that, in turn, organize glutamatergic
transmission (Daoud et al., 2009), thereby illustrating another
relation with (hyper) excitation and consequently TLE.
Based on the previous, an upregulation of the DMD gene
could result in more dystrophin transcription and hence multiple
potential compensatory mechanisms that could restore the
balance between excitation and inhibition in brains that are
prone to hyperexcitation. This could also partly clarify why
the prevalence of epilepsy is increased in patients with DMD.
Notwithstanding the fact that a dystrophin absence could
theoretically also result in epilepsy (Pane et al., 2013; Hendriksen
et al., 2015), a mutation in the DMD gene also impairs
the occurrence of the abovementioned potential compensatory
mechanism. Furthermore, the lack of such mechanisms could
theoretically be, analogous to the cognitive deficits that are
often seen in DMD (Ricotti et al., 2016), mutation dependent;
a more distal mutation affects more brain isoforms and would
thus give rise to multiple deficient counteracting mechanisms
(i.e., both neuronal and glial mediated), hence increasing the
probability of hyperexcitable brain (networks) and thereby
epilepsy.
The discrepancy between human and experimental TLE
data regarding dystrophin expression is interesting. Possibly,
this can be explained by the presence of neuronal cell loss
and gliosis in human TLE, which is absent in AK since this
model is not characterized by neurodegeneration (Brandt et al.,
2004). Indeed, Heuser et al. (2012) demonstrated a difference
in dystrophin immunoreactivity in epilepsy patients with and
without hippocampal sclerosis. However, in this study we did
not find such a difference in dystrophin expression between
these two groups. Another possible explanation is that in
humans, the tissue from which the seizure originated was
evaluated, while in rats the contralateral hippocampus was
used in order to exclude the influence of direct electrical
stimulation. Moreover, in contrast to the kindled rats, all human
patients suffered from chronic and intractable epilepsy that
has been tried to manage for years before epilepsy surgery
was performed. The compensatory mechanisms hypothesized
above may only develop over years in-vivo, and not after
the relatively short period (i.e., 3 weeks) of experimental
seizures.
Limitations and Future Perspectives
This study also has its limitations. First of all, the full-length
isoform was based on immunofluorescence neither visualized
in cerebellum nor in hippocampus. Additionally, for ethical
reasons we were not able to include human cerebellar tissue in
this study. For rats, cerebellar rat tissue was treated differently
in the Western blot procedure since it was paraformaldehyde
fixed. As the material from the experimental AK group has
been treated in the same way, this should not have affected the
relative difference between the two groups. Furthermore, the
two groups included in the analysis of the cerebellum are small.
Inevitably, the average age of the post-mortem control patients
was – logically – substantially higher than the average age of the
epilepsy patients, which could have influenced the quantitative
expression of neuronal proteins.
Future research should focus on studying dystrophin
expression in different brain areas in order to better understand
the possible association between hyperexcitation and dystrophin
alterations, since this relation has only been marginally
addressed in literature. Conversely the role of dystrophin in
(hyper)excitation should be further evaluated using animal
models in which different dystrophin isoforms are absent, ideally
by making use of electrical kindling techniques, such as in this
study applied and which has not been studied before. Ultimately,
future studies should disentangle the possible contribution of the
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different dystrophin isoforms to epileptogenesis in order to assess
possibilities for new anti-epileptic therapies.
CONCLUSION
Dystrophin is ubiquitously expressed in the hippocampus and
cerebellum of AK rats and in human hippocampal tissue from
epilepsy patients with and without HS as proven by Western
blot and immunofluorescent analysis in this study. Dp427, which
principal function in the brain it is to anchor GABAA receptors
in the post-synaptic membrane, is increased in human epileptic
hippocampi, possibly as a compensatory mechanism in order
to restore the inhibitory balance in hyperexcitable brains. This
is the first study that reports on a (full-length) dystrophin
upregulation in epilepsy, which justifies more research in order
to further investigate this newly emerging relationship between
hyperexcitation and dystrophin. Future studies should address
how the different brain dystrophin isoforms are related to
hyperexcitation, in what direction this relationship may be
established and, ultimately, whether dystrophin may represent a
novel target for seizure treatment.
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